Published in Br J Pharmacol on August 26, 2003
Alarin is a vasoactive peptide. Proc Natl Acad Sci U S A (2007) 0.97
Perivascular innervation: a multiplicity of roles in vasomotor control and myoendothelial signaling. Microcirculation (2013) 0.87
Endogenous neuropeptide Y depresses the afferent signaling of gastric acid challenge to the mouse brainstem via neuropeptide Y type Y2 and Y4 receptors. Neuroscience (2005) 0.87
Tear levels of neuropeptides increase after specific allergen challenge in allergic conjunctivitis. Mol Vis (2011) 0.84
Neuropeptide Y2 receptors are involved in enhanced neurogenic vasoconstriction in spontaneously hypertensive rats. Br J Pharmacol (2006) 0.80
Neuropeptide Y and neurovascular control in skeletal muscle and skin. Am J Physiol Regul Integr Comp Physiol (2009) 0.79
Gut hormone PYY(3-36) physiologically inhibits food intake. Nature (2002) 8.30
Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature (1982) 4.06
Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand (1982) 3.25
XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev (1998) 2.58
Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept (1984) 2.27
Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade. Acta Physiol Scand (1982) 2.23
Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity. J Pharmacol Methods (1990) 1.89
Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med (1998) 1.70
Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res (1998) 1.62
Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci U S A (1992) 1.53
[Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist. Proc Natl Acad Sci U S A (1990) 1.50
Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol (1984) 1.46
Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept (1993) 1.42
BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur J Pharmacol (1999) 1.38
Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc Natl Acad Sci U S A (2002) 1.37
Prolonged non-adrenergic inhibition of cardiac vagal action following sympathetic stimulation: neuromodulation by neuropeptide Y? Neurosci Lett (1985) 1.37
Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol (1998) 1.28
Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci U S A (2003) 1.28
Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gut. Regul Pept (1984) 1.26
Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept (1994) 1.25
Selectivity of neutrophil 5-lipoxygenase and cyclo-oxygenase inhibition by an anti-inflammatory flavonoid glycoside and related aglycone flavonoids. J Pharm Pharmacol (1988) 1.24
Vasoactive peptides in the skin. J Investig Dermatol Symp Proc (1997) 1.12
Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor. Nature (2001) 1.12
Neuropeptide Y, Y1, Y2 and Y4 receptors mediate Y agonist responses in isolated human colon mucosa. Br J Pharmacol (2002) 1.09
BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist. Br J Pharmacol (2000) 1.08
Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides (2003) 1.03
Co-release of neuropeptide Y and catecholamines during physical exercise in man. Biochem Biophys Res Commun (1985) 1.03
Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. J Biol Chem (1995) 0.99
Neuropeptide Y-induced angiogenesis in aging. Peptides (2002) 0.99
Functional consequences of neuropeptide Y Y 2 receptor knockout and Y2 antagonism in mouse and human colonic tissues. Br J Pharmacol (2003) 0.98
Use of NK(1) knockout mice to analyze substance P-induced edema formation. Am J Physiol (1999) 0.98
Evidence for two neuropeptide Y receptors mediating vasoconstriction. Eur J Pharmacol (1991) 0.96
Neuropeptide Y: immunocytochemical localization to and effect upon feline pial arteries and veins in vitro and in situ. Acta Physiol Scand (1984) 0.96
Broad spectrum antibiotic activity of the skin-PYY. FEBS Lett (1996) 0.96
Multiple Y receptors mediate pancreatic polypeptide responses in mouse colon mucosa. Peptides (2001) 0.96
Possible location and function of neuropeptide Y receptor subtypes in the rat mesenteric arterial bed. J Pharmacol Exp Ther (1992) 0.95
Effects of various neuropeptide Y/peptide YY fragments on electrically-evoked contractions of the rat vas deferens. Br J Pharmacol (1990) 0.91
Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226. Br J Pharmacol (1995) 0.91
Neuropeptide Y Y1 and neuropeptide Y Y2 receptors in human cardiovascular tissues. Peptides (2002) 0.88
Vascular pharmacology of BIIE0246, the first selective non-peptide neuropeptide Y Y(2) receptor antagonist, in vivo. Br J Pharmacol (2001) 0.88
Multiple peptides in cutaneous nerves: regulators under physiological conditions and a pathogenetic role in skin disease? Semin Dermatol (1988) 0.87
Characterization of vascular postsynaptic NPY receptor function and regulation and differential sensitivity of Y1 and Y2 receptor function to changes in extracellular calcium availability and prior in vitro peptide exposure. Neuropeptides (1993) 0.86
Cotransmission from sympathetic vasoconstrictor neurons to small cutaneous arteries in vivo. Am J Physiol (1999) 0.86
Neurokinin B induces oedema formation in mouse lung via tachykinin receptor-independent mechanisms. J Physiol (2002) 0.85
Nerve fibers containing neuropeptide Y in the cerebrovascular bed: immunocytochemistry, radioimmunoassay, and vasomotor effects. J Cereb Blood Flow Metab (1987) 0.85
Effects of the neuropeptide Y Y2 receptor antagonist BIIE0246 on sympathetic transmitter release in the pig in vivo. Naunyn Schmiedebergs Arch Pharmacol (2001) 0.84
Selective constriction of small cutaneous arteries by NPY matches distribution of NPY in sympathetic axons. Regul Pept (1994) 0.83
Pharmacology of neuropeptide Y receptor antagonists. Focus on cardiovascular functions. Eur J Pharmacol (2002) 0.82
C-terminal neuropeptide Y fragments are mast cell-dependent vasodepressor agents. Eur J Pharmacol (1991) 0.82
Characterization and molecular cloning of vascular neuropeptide Y receptor subtypes in pig and dog. Regul Pept (1998) 0.80
Effects of the neuropeptide YY1 receptor antagonist SR 120107A on sympathetic vascular control in pigs in vivo . Naunyn Schmiedebergs Arch Pharmacol (1996) 0.79
Cutaneous vasomotor effects of neuropeptide Y. Neuropeptides (1995) 0.79
Neuropeptide Y and galanin are coexpressed in rat large type A sensory neurons after peripheral transection. Peptides (1994) 0.79
Langerhans cell expression of neuropeptide Y and peptide YY. Neuropeptides (2002) 0.78
The calcitonin gene-related peptide (CGRP) antagonist CGRP(8-37) blocks vasodilatation in inflamed rat skin: involvement of adrenomedullin in addition to CGRP. Neurosci Lett (2001) 0.78
Noradrenergic and peptidergic sympathetic regulation of cutaneous microcirculation in the rat. Eur J Pharmacol (1997) 0.78
Role of neuropeptide Y in the development of two-kidney, one-clip renovascular hypertension in the rat. J Vasc Surg (2000) 0.77
Contractile effects of neuropeptide Y in human subcutaneous resistance arteries are mediated by Y1 receptors. J Cardiovasc Pharmacol (1996) 0.77
Gut hormone PYY(3-36) physiologically inhibits food intake. Nature (2002) 8.30
Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med (2007) 3.36
Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab (2006) 2.23
Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med (2007) 2.20
Hypothalamic Y2 receptors regulate bone formation. J Clin Invest (2002) 2.01
Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses. Cell Metab (2010) 1.71
NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides (2004) 1.63
Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology (2008) 1.53
Common structural basis for constitutive activity of the ghrelin receptor family. J Biol Chem (2004) 1.49
Y4 receptor knockout rescues fertility in ob/ob mice. Genes Dev (2002) 1.38
Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc Natl Acad Sci U S A (2002) 1.37
Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur J Neurosci (2003) 1.36
Arcuate NPY controls sympathetic output and BAT function via a relay of tyrosine hydroxylase neurons in the PVN. Cell Metab (2013) 1.33
The central and basolateral amygdala are critical sites of neuropeptide Y/Y2 receptor-mediated regulation of anxiety and depression. J Neurosci (2010) 1.29
Characterization of neuropeptide Y2 receptor protein expression in the mouse brain. I. Distribution in cell bodies and nerve terminals. J Comp Neurol (2006) 1.28
Neuropeptide Y stimulates neuronal precursor proliferation in the post-natal and adult dentate gyrus. J Neurochem (2005) 1.26
A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med (2005) 1.25
Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Br J Pharmacol (2006) 1.24
c-Cbl-deficient mice have reduced adiposity, higher energy expenditure, and improved peripheral insulin action. J Clin Invest (2004) 1.18
Neuropeptide Y is neuroproliferative for post-natal hippocampal precursor cells. J Neurochem (2003) 1.18
Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J Biol Chem (2007) 1.14
The transient receptor potential vanilloid 1 (TRPV1) receptor protects against the onset of sepsis after endotoxin. FASEB J (2007) 1.14
Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem (2007) 1.14
Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors. Brain (2007) 1.13
TGF-b superfamily cytokine MIC-1/GDF15 is a physiological appetite and body weight regulator. PLoS One (2013) 1.12
A distinct role for transient receptor potential ankyrin 1, in addition to transient receptor potential vanilloid 1, in tumor necrosis factor α-induced inflammatory hyperalgesia and Freund's complete adjuvant-induced monarthritis. Arthritis Rheum (2011) 1.12
Macrophage inhibitory cytokine 1 (MIC-1/GDF15) decreases food intake, body weight and improves glucose tolerance in mice on normal & obesogenic diets. PLoS One (2012) 1.12
Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Nephrol Dial Transplant (2011) 1.12
Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation. Arthritis Rheum (2005) 1.11
Behavioural profile of a new mouse model for NPY deficiency. Eur J Neurosci (2008) 1.10
The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y and not Y receptors. Eur J Neurosci (2005) 1.10
Evidence for the pathophysiological relevance of TRPA1 receptors in the cardiovascular system in vivo. Cardiovasc Res (2010) 1.10
Hypothalamic control of bone formation: distinct actions of leptin and y2 receptor pathways. J Bone Miner Res (2005) 1.10
Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice. Behav Brain Res (2003) 1.09
The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol Ther (2011) 1.09
Effect of high-fat feeding on expression of genes controlling availability of dopamine in mouse hypothalamus. Nutrition (2009) 1.08
Importance of constitutive activity and arrestin-independent mechanisms for intracellular trafficking of the ghrelin receptor. Mol Endocrinol (2007) 1.07
Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS One (2009) 1.04
Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol Cell Biol (2003) 1.03
Neuropeptide Y and peptide YY: important regulators of energy metabolism. Curr Opin Endocrinol Diabetes Obes (2011) 1.02
Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J Bone Miner Res (2006) 1.02
Neuropeptide Y is important for basal and seizure-induced precursor cell proliferation in the hippocampus. Neurobiol Dis (2006) 1.01
Behavioral profiling of NPY in aggression and neuropsychiatric diseases. Peptides (2006) 1.01
NPY regulation of bone remodelling. Neuropeptides (2009) 0.99
Functional consequences of neuropeptide Y Y 2 receptor knockout and Y2 antagonism in mouse and human colonic tissues. Br J Pharmacol (2003) 0.98
A role for TRPV1 in influencing the onset of cardiovascular disease in obesity. Hypertension (2012) 0.98
Y2 receptor deletion attenuates the type 2 diabetic syndrome of ob/ob mice. Diabetes (2002) 0.98
Neurovascular aspects of skin neurogenic inflammation. J Investig Dermatol Symp Proc (2011) 0.98
Neuropeptide Y in the recurrent mossy fiber pathway. Peptides (2007) 0.97
Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity. J Bone Miner Res (2010) 0.97
Differential actions of NPY on seizure modulation via Y1 and Y2 receptors: evidence from receptor knockout mice. Epilepsia (2006) 0.97
Alarin is a vasoactive peptide. Proc Natl Acad Sci U S A (2007) 0.97
Evidence of a role for NK1 and CGRP receptors in mediating neurogenic vasodilatation in the mouse ear. Br J Pharmacol (2002) 0.97
Y1 receptors are critical for the proliferation of adult mouse precursor cells in the olfactory neuroepithelium. J Neurochem (2007) 0.97
NPY receptors as potential targets for anti-obesity drug development. Br J Pharmacol (2011) 0.96
TRPV1 deletion enhances local inflammation and accelerates the onset of systemic inflammatory response syndrome. J Immunol (2012) 0.95
Characterization of neuropeptide Y, Y(2) receptor knockout mice in two animal models of learning and memory processing. J Mol Neurosci (2004) 0.95
Osteoblast specific Y1 receptor deletion enhances bone mass. Bone (2010) 0.95
Evidence from knockout mice that peptide YY and neuropeptide Y enforce murine locomotion, exploration and ingestive behaviour in a circadian cycle- and gender-dependent manner. Behav Brain Res (2009) 0.94
Neutrophils-derived peroxynitrite contributes to acute hyperalgesia and cell influx in zymosan arthritis. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.94
Neuropeptide Y2 receptor protein is present in peptidergic and nonpeptidergic primary sensory neurons of the mouse. J Comp Neurol (2005) 0.94
The Y1 receptor for NPY: a key modulator of the adaptive immune system. Peptides (2007) 0.93
Tachykinins regulate the function of platelets. Blood (2004) 0.93
PYY transgenic mice are protected against diet-induced and genetic obesity. Neuropeptides (2007) 0.93
NPY neuron-specific Y2 receptors regulate adipose tissue and trabecular bone but not cortical bone homeostasis in mice. PLoS One (2010) 0.92
The role of peptide YY in regulating glucose homeostasis. Peptides (2007) 0.92
Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety. Behav Brain Res (2005) 0.92
Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. J Biol Chem (2006) 0.92
Mouse models of Prader-Willi Syndrome: a systematic review. Front Neuroendocrinol (2013) 0.92
Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease. Neurobiol Aging (2011) 0.92
Salivary PYY: a putative bypass to satiety. PLoS One (2011) 0.92
NPY and receptors in immune and inflammatory diseases. Curr Top Med Chem (2007) 0.92
Gastrointestinal hormones (anorexigenic peptide YY and orexigenic ghrelin) influence neural tube development. FASEB J (2007) 0.91
4-oxo-2-nonenal (4-ONE): evidence of transient receptor potential ankyrin 1-dependent and -independent nociceptive and vasoactive responses in vivo. J Pharmacol Exp Ther (2011) 0.91
Hypothalamic regulation of energy homeostasis. Best Pract Res Clin Endocrinol Metab (2002) 0.91
A reactive oxygen species-mediated component in neurogenic vasodilatation. Cardiovasc Res (2008) 0.91
Y(4) receptors mediate the inhibitory responses of pancreatic polypeptide in human and mouse colon mucosa. J Pharmacol Exp Ther (2006) 0.90
Peptide YY regulates bone remodeling in mice: a link between gut and skeletal biology. PLoS One (2012) 0.90
Peptidergic influences on proliferation, migration, and placement of neural progenitors in the adult mouse forebrain. Proc Natl Acad Sci U S A (2008) 0.90
Distribution of prodynorphin mRNA and its interaction with the NPY system in the mouse brain. Neuropeptides (2006) 0.90
Role of the C terminus in neuropeptide Y Y1 receptor desensitization and internalization. Mol Pharmacol (2004) 0.89
The regulation of veratridine-stimulated electrogenic ion transport in mouse colon by neuropeptide Y (NPY), Y1 and Y2 receptors. Br J Pharmacol (2005) 0.89
Calcitonin gene-related peptide (CGRP) and its role in hypertension. Neuropeptides (2011) 0.89
NPY revealed as a critical modulator of osteoblast function in vitro: new insights into the role of Y1 and Y2 receptors. J Cell Biochem (2009) 0.89
An ongoing role of α-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension (2014) 0.89
Postprandial cardiac autonomic function in Prader-Willi syndrome. Clin Endocrinol (Oxf) (2013) 0.88
Role of neuropeptide Y Y(2) receptors in modulation of cardiac parasympathetic neurotransmission. Regul Pept (2002) 0.88
Sex-dependent control of murine emotional-affective behaviour in health and colitis by peptide YY and neuropeptide Y. Br J Pharmacol (2011) 0.88
Stress-induced suppression of the gonadotropin-releasing hormone pulse generator in the female rat: a novel neural action for calcitonin gene-related peptide. Endocrinology (2004) 0.88
Combined deletion of Y1, Y2, and Y4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity. Endocrinology (2006) 0.88
Peripheral-specific y2 receptor knockdown protects mice from high-fat diet-induced obesity. Obesity (Silver Spring) (2011) 0.87
Reactive nitrogen species scavenging, rather than nitric oxide inhibition, protects from articular cartilage damage in rat zymosan-induced arthritis. Br J Pharmacol (2003) 0.87
Implication of neuropeptide-Y Y2 receptors in the effects of immune stress on emotional, locomotor and social behavior of mice. Neuropharmacology (2008) 0.87
Schwann cell-specific JAM-C-deficient mice reveal novel expression and functions for JAM-C in peripheral nerves. FASEB J (2011) 0.87
Adult-onset hippocampal-specific neuropeptide Y overexpression confers mild anxiolytic effect in mice. Eur Neuropsychopharmacol (2009) 0.87
Sensory-nerve-derived neuropeptides: possible therapeutic targets. Handb Exp Pharmacol (2009) 0.86
Y1 receptors regulate aggressive behavior by modulating serotonin pathways. Proc Natl Acad Sci U S A (2004) 0.86